Hypokalemia and hypomagnesaemia related to levetiracetam use

Aksoy, Dürdane; Çevik, Betül; Kurt, Semiha; Pekdaş, Elmas; Solmaz, Volkan

doi:10.1016/j.jocn.2014.03.013

Cited by 14 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two of the four case reports attributing acute interstitial nephritis to levetiracetam use had biopsy confirmation (9,10), whereas another case attributed hypokalemia and hypomagnesemia to an acquired kidney tubular disorder secondary to levetiracetam use (34). The product monograph for levetiracetam lists nephritis as a possible manifestation associated with Drug Reaction with Eosinophilia and Systemic Symptoms.…”

Section: Discussionmentioning

confidence: 99%

Population-Based Study of Risk of AKI with Levetiracetam

Yau

Burneo

Jandoc

et al. 2018

CJASN

View full text Add to dashboard Cite

Background and objectives Regulatory agencies warn about the risk of AKI with levetiracetam use on the basis of information from case reports. We conducted this study to determine whether new levetiracetam use versus nonuse is associated with a higher risk of AKI.Design, setting, participants, & measurements This was a population-based retrospective cohort study of adults with epilepsy in Ontario, Canada. Patients who received a new outpatient prescription for levetiracetam between January 1, 2004 and March 1, 2017 were matched to two nonusers on stage of CKD, recorded seizure in the prior 90 days, and logit of a propensity score for levetiracetam use. The primary outcome was a hospital encounter (emergency department visit or hospitalization) with AKI within 30 days of cohort entry. Secondary outcomes were AKI within 180 days and change in the concentration of serum creatinine. We assessed the primary outcome using health care diagnosis codes. We evaluated the change in the concentration of serum creatinine in a subpopulation with laboratory measurements. ResultsWe matched 3980 levetiracetam users to 7960 nonusers (mean age 55 years, 51% women). Levetiracetam use was not significantly associated with a higher risk of AKI within 30 days (13 [0.33%] events in levetiracetam users and 21 [0.26%] events in nonusers [odds ratio, 1.24; 95% confidence interval, 0.62 to 2.47]). Similarly, there was no significant association with AKI within 180 days (odds ratio, 0.70; 95% confidence interval, 0.43 to 1.13). The change in the concentration of serum creatinine did not significantly differ between levetiracetam users and nonusers. ConclusionsIn this population-based study levetiracetam use was not associated with a higher risk of AKI.

show abstract

Section: Discussionmentioning

confidence: 99%

Population-Based Study of Risk of AKI with Levetiracetam

Yau

Burneo

Jandoc

et al. 2018

CJASN

View full text Add to dashboard Cite

show abstract

“…Shakya et al [12] reported auditory hallucinations in the 3rd week of LEV use in a 32-yearold patient with refractory epilepsy and that these symptom resolved 3 days after drug discontinuation. Aksoy et al [13] determined hypokalemia and hypomagnesemia 1 month after LEV use in a 23-year-old male patient and reported that this electrolyte imbalance resolved after gradual drug discontinuation. Other rare side-effects of LEV are skin lesions and hair loss [14].…”

Section: Discussionmentioning

confidence: 99%

A Rare Complication of Levetiracetam Theraphy: Hallucination

Erdoğan¹

2017

North Clin Istanbul

View full text Add to dashboard Cite

Levetiracetam is a new antiepileptic drug. In addition to epilepsy, it is also used for treating anxiety disorders and dystonia as well as tardive dyskinesia associated with the use of levodopa and neuroleptic drugs. Phenytoin therapy in a 10-year-old boy with convulsions was discontinued following cardiac rhythm impairment. The patient was then started on levetiracetam. However, visual and auditory hallucinations were observed on the 1st day of levetiracetam therapy. Levetiracetam was discontinued and replaced with sodium valproate, and the hallucinations resolved. The purpose of this report was to remind physicians that hallucinations are one of the rare complications of levetiracetam.

show abstract

“…1 Lev-associated hyponatremia, hypokalemia, and hypomagnesemia have been described in adult patients. [2][3][4][5][6][7][8] However, there are no reports on the above Lev-associated disorders in children with epilepsy treated with Lev monotherapy.…”

Section: Serum Sodium Potassium and Magnesium In Children With Epilmentioning

confidence: 99%